#USA #Milford #Waters Corporation #BD #Biosciences

Waters Corporation's Major Milestone

Waters Corporation recently reached a significant milestone in its corporate strategy by announcing that shareholders have overwhelmingly approved its merger with BD's Biosciences and Diagnostic Solutions business. This development occurred during a special shareholder meeting held on January 27, 2026, where an impressive 99% of votes were in favor of the transaction.

Udit Batra, Ph.D., President and CEO of Waters Corporation, expressed gratitude towards the shareholders for their support, emphasizing the importance of this approval as a step towards completing the acquisition. Batra noted that this merger is a vital part of Waters' strategy to position itself as a leader in both life sciences and diagnostics, aiming to drive innovation and create value for a diverse range of stakeholders, including patients, customers, and employees.

The approval paves the way for Waters to acquire shares from Becton, Dickinson and Company (BD), a move that allows it to enhance its technological capabilities and service offerings in the life sciences sector. Waters has indicated that the deal is expected to close on February 9, 2026, assuming all customary closing conditions are met.

A Vision for Innovation

As Waters Corporation prepares to integrate BD's capabilities, the company is focused on leveraging the strengths of both entities to accelerate advancements in analytical science. The acquisition is seen as a strategic opportunity not only for expanding Waters’ product portfolio but also for enhancing the accessibility and efficiency of diagnostics and healthcare solutions globally.

In an environment where technological advancements in biosciences are imperative for addressing public health challenges, Waters aims to harness the merged resources effectively. The company serves over 100 countries, and with more than 7,600 dedicated employees, it is poised to operate at an even greater scale as a result of this merger.

Regulatory Approvals and Financial Plans

Waters Corporation has also received all required regulatory approvals for the merger, including a favorable Private Letter Ruling from the Internal Revenue Service regarding the U.S. federal income tax implications. This proactive approach satisfies one of the crucial conditions necessary for finalizing the acquisition, reflecting Waters' diligence in adhering to regulatory standards.

Additionally, the company has scheduled its Q4 2025 financial results conference call for February 9, 2026, at 8:30 a.m. Eastern Time. This coinciding timing not only serves to inform stakeholders about the company’s financial health but also aligns with the anticipated close of the transaction, providing a comprehensive overview of Waters’ future direction post-merger.

Looking Forward

As Waters Corporation embarks on this journey with BD, the focus will remain on achieving meaningful growth through innovation in diagnostics and life sciences. The integration process is poised to introduce enhanced synergies, promising a transformative impact on the industry. Stakeholders are urged to stay informed by following the developments through official investor channels as the company transitions into this new chapter of its growth story.

In conclusion, this acquisition signifies Waters Corporation's commitment to strengthening its market position and expanding its capabilities within the life sciences landscape. With a forward-looking approach and the backing of its shareholders, Waters is well-prepared to lead with innovative solutions that cater to the needs of patients and the healthcare sector at large.